CDH Investments Management
Chinese rocket developer i-Space raises $173m
Chinese commercial rocket developer i-Space - also known as Interstellar Glory Space - has raised a RMB1.2 billion ($173 million) Series B round led by State-owned Beijing Financial Street Capital Operation Center.
Uncertainty deters distress investors - M&A Forum
Distress-focused investors warned that persistent economic uncertainty is making it difficult to act on opportunities even as companies run into trouble because of the coronavirus pandemic.
China's Vision Medicals raises $28m
CDH Investment has led a RMB200 million ($28 million) Series B round for Guangzhou-based precision diagnosis and gene sequencing company Vision Medicals.
CDH leads round for China community group buying player
Shihuituan, a China-based community group buying platform also known as Nice Tuan, has raised $80 million in the second tranche of a Series C round led by CDH Investments.
China gay dating app Blued raises $85m in US IPO
BlueCity Holdings, the VC-backed holding company for Chinese gay dating platform Blued, traded strongly after raising $84.8 million through a NASDSAQ IPO.
China LGBTQ investments: Pink power
There has been little VC investment in Chinese LGBTQ social platforms since 2017 due to regulatory concerns. Will gay dating site Blued’s US IPO reignite interest in the space?
VC-backed SinocellTech enjoys strong Star Market debut
Chinese drug developer SinocellTech nearly trebled in value on its first day of trading on China's Science and Technology Innovation Board (Star Market) following a RMB1.28 billion ($181 million) IPO.
China gay dating app Blued pursues US IPO
BlueCity Holdings, the company behind Chinese gay dating platform Blued, has filed an application to list on NASDAQ, which would provide a liquidity event for several PE and VC investors.
China mezzanine: Not the norm
China’s local currency mezzanine capital space is underpenetrated, underpopulated and different to comparable strategies elsewhere. A handful of domestic GPs have begun to get traction. Will others follow?
Dragon Ball, CDH lead Series C in China's Lehe Food
Lehe Food, a China-based distributor of fresh food and ingredients, has secured RMB400 million ($56 million) in Series C funding led by Dragon Ball Capital and CDH Investments. Existing backer Hezhi Investment re-upped.
CDH raises $1.1b for China's largest mezzanine fund
CDH Investments has closed its fifth China mezzanine fund at RMB8 billion ($1.1 billion). It is the largest vehicle of its kind ever raised solely for deployment in the country.
Jumpstarted: Investors target China's EV charging networks
Telaidian’s recent Series A round underlines the opportunities in China’s electric vehicle charging space. While growth seems certain, some industry dynamics have yet to play out
PE targets sensual wellness: Good vibrations
A recent commitment by China’s CDH Investments to Wow Tech underlines how sensual health products such as vibrators are moving from the margins to the mainstream, globally and in Asia
CDH closes sixth China PE fund at $1.5b
CDH Investments has closed its sixth flagship US dollar-denominated fund with $1.5 billion in commitments. The initial target was $2.5 billion.
China’s GenFleet Therapeutics raises $50m Series B
CDH Investments and Shenzhen Capital Group have co-led a $50 million Series B round for GenFleet Therapeutics, a Chinese drug developer.
China EV charging operator secures $190m Series A
Telaidian, which claims to operate China's largest electric vehicle (EV) charging network, has raised RMB1.35 billion ($190 million) in Series A funding.
CITIC, CDH, Legend invest $300m in China freight business
CITIC Capital, CDH investments and Legend Capital have invested $300 million in SF Freight, a sub-brand of Chinese courier company SF Express, through a convertible note issue.
China space tech: Aligning the stars
SpaceX-inspired global fervor about the possibilities of space technology has infiltrated China. Some start-ups appear well set for commercial lift-off, but many others will misfire
China's I-Mab falls on US debut after $104m IPO
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
Chinese biopharma player secures $100m Series B
Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.
Deal focus: China's Benlai takes a different approach to group buying
Community group buying businesses are beginning to struggle in China despite considerable VC investment. Fresh produce retailer Benlai believes its online-to-offline hybrid model is more sustainable
China property marketplace trades flat after $78m IPO
Chinese online real estate marketplace Fangdd Network raised $78 million in its US IPO, having reduced the size of the offering, and traded flat on its first day on NASDAQ.
China's I-Mab Biopharma pursues US IPO
I-Mab Biopharma, the product of a CBC Group-engineered merger of two Chinese drug developers, has announced plans for a NASDAQ IPO.
Chinese online property marketplace set for IPO
Fangdd Network, a Chinese online real estate marketplace backed by the likes of FountainVest Partners and CDH Investments, has filed to list in the US.